1. Scrip
  2. >>Archive

Shire extends ViroPharma offer while OFT deliberates

 
• By Eleanor Malone

Although enough shares have already been tendered, Shire has extended its $4.2bn tender offer for the US orphan disease drug maker ViroPharma for a second time. The company told Scrip that it was waiting for clearance for the merger from the UK's Office of Fair Trading. The competition authority's decision is due on 10 February.

Although enough shares have already been tendered, Shire has extended its $4.2bn tender offer for the US orphan disease drug maker ViroPharma for a second time. The company told Scrip that it was waiting for clearance for the merger from the UK's Office of Fair Trading. The competition authority's decision is due on 10 February.

Shire and ViroPharma both sell products for the rare disease hereditary angioedema (HAE), but whereas ViroPharma's Cinryze (human C1 esterase inhibitor) is used preventively, Shire's Firazyr (icatibant injection) is used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.